Rankings
▼
Calendar
ESLA Q4 2024 Earnings — Estrella Immunopharma, Inc. Revenue & Financial Results | Market Cap Arena
ESLA
Estrella Immunopharma, Inc.
$53M
Q4 2024 Earnings
Healthcare
Biotechnology
Income Statement
Revenue
$0
Gross Profit
$0
Operating Income
-$1M
Net Income
-$1M
EPS (Diluted)
$-0.03
QoQ Revenue Growth
NaN%
Cash Flow
Operating Cash Flow
-$896,066
Free Cash Flow
-$896,070
Stock-Based Comp.
$0
Balance Sheet
Total Assets
$3M
Total Liabilities
$3M
Stockholders' Equity
$143,731
Cash & Equivalents
$916,916
Year-over-Year Comparison
Metric
Current
Year Ago
Change
Revenue
$0
$0
—
Gross Profit
$0
$0
—
Operating Income
-$1M
-$1M
-2.9%
Net Income
-$1M
-$1M
-2.9%
← FY 2024
All Quarters
Q1 2025 →